Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in The Journal of Urology, an Official Journal of the American Urological Association.
Investigators at Cedars-Sinai have created a unique and detailed molecular profile of endometriosis to help improve therapeutic options for the millions of women suffering from the disease.
Up to 15% of women of reproductive age in the United States suffer from endometriosis, a condition characterized by pelvic pain, menstrual cramps and infertility.
A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.
New research from Yale Cancer Center identified that two simple biomarkers, immune cells and estrogen receptor levels, could differentiate which young women with ER+ breast cancer need chemotherapy to improve their survival, and which only need a monthly injection to suppress ovarian function.
For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
Researchers explored the molecular and cellular mechanisms of SARS-CoV-2 infection.
Researchers are exploring a potential new therapeutic approach for triple negative breast cancer treatment.
A new perspective by researchers from the American Cancer Society and the University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality in African American (Black) women versus White women began in the United States in the 1980's.
Genetics and other factors that can determine if a woman is at risk for a recurrence of breast cancer have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing new research avenues for preventing a new tumor from developing.
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show.
Gender-affirming hormone therapy could influence the way a person's genes are turned on or off, according to a new study.
Many cases of early prostate cancer are dominated by cells that are slow-growing, often leading to a clinical decision to monitor for progression before initiating treatments that can have adverse side effects.
In this interview, News-Medical talks to Dr. Simon Chowdhury and Laetitia Guilloux about the current state of prostate cancer, it's prevalence, treatment options and its future.
Use of menopausal hormone therapy (MHT, also known as hormone replacement therapy, HRT) is not associated with an increased risk of developing dementia, regardless of hormone type, dose, or duration, concludes a large UK study published by The BMJ.
A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
South Australian medical researchers have identified a new way in which prostate cancer cells use glucose to grow and survive, which in turn could be the secret to destroying them.
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center.
A group of Belgium researchers recently discuss their findings in the journal Microorganisms, which describe the influence of several factors on vaccine-induced immunogenicity.